Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

Company Overview

Y-mAbs Therapeutics is a clinical‐stage biopharmaceutical company focused on developing antibody-based cancer immunotherapies for pediatric and adult patients. Leveraging proprietary antibody engineering and radiolabeling platforms, the company targets solid tumors and central nervous system malignancies that express the GD2 antigen. Its research approach combines monoclonal antibodies with radioconjugates to selectively deliver therapeutic payloads to cancer cells.

The company’s lead product, DANYELZA (naxitamab-gqgk), received U.S. Food and Drug Administration approval in 2020 for the treatment of high-risk neuroblastoma in pediatric and young adult patients whose disease has not progressed after multi-cycle chemotherapy. In addition to its marketed therapy, Y-mAbs is advancing omburtamab, a radiolabeled monoclonal antibody designed to target metastatic or leptomeningeal tumors in the central nervous system. The pipeline also includes earlier-stage antibody candidates exploring novel targets in solid tumors.

Headquartered in New York, Y-mAbs is domiciled in Switzerland and conducts clinical trials across North America, Europe and Australia. Commercial operations for DANYELZA extend into the United States and Canada, with expanded access programs facilitating treatment for patients outside traditional trial settings. Through collaborations with leading research institutions, the company continues to broaden its development footprint in pediatric oncology.

Founded in 2016 out of collaborative research efforts, Y-mAbs operates under a management team with extensive experience in oncology drug development and regulatory strategy. The company’s scientific leadership and board comprise veterans of both large-cap pharmaceutical firms and specialized biotech startups, supporting its mission to bring targeted immunotherapies to underserved cancer populations.

Key Stats

• Today's Range: $8.61 to $8.61
• 50-Day Range: $4.19 to $8.61
• 52-Week Range: $3.55 to $16.11
• Volume: N/A
• Average Volume: 676,583 shs
• Market Capitalization: $391.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.62
• Consensus Rating: Reduce

Y-mAbs Therapeutics Stock Analysis - MarketRank™

Y-mAbs Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 743rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Y-mAbs Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 8 hold ratings, and 2 sell ratings.

Upside Potential

Y-mAbs Therapeutics has a consensus price target of $9.62, representing about 11.8% upside from its current price of $8.61.

Amount of Analyst Coverage

Y-mAbs Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Y-mAbs Therapeutics is -17.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Y-mAbs Therapeutics is -17.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Y-mAbs Therapeutics has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.36% of the float of Y-mAbs Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Y-mAbs Therapeutics has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Y-mAbs Therapeutics does not currently pay a dividend.

Dividend Growth

Y-mAbs Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.36% of the float of Y-mAbs Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Y-mAbs Therapeutics has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.70% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

YMAB Stock Analysis - Frequently Asked Questions

How have YMAB shares performed this year?

Y-mAbs Therapeutics' stock was trading at $7.83 on January 1st, 2025. Since then, YMAB stock has increased by 10.0% and is now trading at $8.61.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its earnings results on Friday, August, 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. The company had revenue of $19.52 million for the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative trailing twelve-month return on equity of 24.60%.

When did Y-mAbs Therapeutics IPO?

Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 10/05/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:YMAB
• CIK: 1722964
• Web: www.ymabs.com
• Phone: (646) 885-8505
• Fax: N/A
• Employees: 150
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Y-mAbs Therapeutics: $9.62
• High Price Target: $17.00
• Low Price Target: $3.00
• Potential Upside/Downside: +11.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.67 million
• Net Margins: -26.03%
• Pretax Margin: -26.49%
• Return on Equity: -24.60%
• Return on Assets: -18.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.00
• Quick Ratio: 3.58

Sales & Book Value

• Annual Sales: $87.68 million
• Price / Sales: 4.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.05 per share
• Price / Book: 4.20

Miscellaneous

• Outstanding Shares: 45,440,000
• Free Float: 36,487,000
• Market Cap: $391.24 million
• Optionable: Optionable
• Beta: 0.54